Triple agonistInvestigational · Phase 3

Retatrutide

Last updated

Triple GIP, GLP-1, and glucagon receptor agonist. Once weekly.

Retatrutide (investigational)·Eli Lilly

Other GLP-1 medicines at sellers we link to

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

No seller we link to sells retatrutide; these are different medicines, compounded and not FDA-approved. Those sellers pay us if you buy, which never changes a price we show.

Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Data updated . What changed

Average weight lost in its trials

  • 12 mg weekly (TRIUMPH-1)TRIUMPH-1 (Phase 3) · 80 wks
    −28.3% (prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html) (-28.3% at 80 wks · TRIUMPH-1 (Phase 3) · 12 mg weekly (TRIUMPH-1))about 57 lb at 200 lb

Averages from separate trials, so they are not a head-to-head ranking and not a prediction. Pounds apply the percentage to a 200 lb starting weight.

Investigational: not FDA-approved for this or any use. It is still being studied in trials.

Information from FDA labels and published trials, not medical advice.

What to know about Retatrutide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Mean weight change in the cited trial
−28.3% (prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html) (-28.3% at 80 wks · TRIUMPH-1 (Phase 3) · 12 mg weekly (TRIUMPH-1))

TRIUMPH-1 (Phase 3) · 12 mg weekly (TRIUMPH-1)

A1c reduction in the cited trial
−1.5 pp (prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-substantial-weight-loss-and-a1c-reduction-underscoring-its-potential-promise-for-people-with-obesity-and-type-2-diabetes-302891798.html) (-1.5% at 12 mg (TRIUMPH-2, Phase 3 T2D) · TRIUMPH-2 (Phase 3 T2D) · HbA1c change in percentage points)

TRIUMPH-2 (Phase 3 T2D)

Stopped treatment for adverse events
11.3% (prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html) (11.3% vs 4.9% placebo (12 mg) · TRIUMPH-1 (12 mg, 80 wks, obesity))

TRIUMPH-1 (12 mg, 80 wks, obesity)

FDA shortage report
In development

Investigational. Not FDA-approved.

Route & frequency
Once weekly

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

How to read the trial results
  • The pivotal program has fully read out: TRIUMPH-2 (type 2 diabetes) reached up to -20.8% weight loss on the efficacy estimand (-18.8% at 12 mg on the treatment-regimen estimand, The Lancet, October 2026) and up to -1.6% A1c, TRIUMPH-3 (severe obesity with established cardiovascular disease) up to -22.6% at 80 wks, and TRIUMPH-4 (knee osteoarthritis in obesity) up to -28.7% with significant knee-pain reduction. Lilly has guided a US submission in Q1 2027 covering obesity, obstructive sleep apnea, and knee osteoarthritis pain. TRIUMPH-4 (lilly.mediaroom.com)
Indications

Investigational uses

Retatrutide (investigational)

Obesity; type 2 diabetes (investigational)

An investigational triple agonist targeting the GIP, GLP-1, and glucagon receptors; the glucagon arm is intended to increase energy expenditure.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

Retatrutide is investigational. See its registered studies below. Search DailyMed (dailymed.nlm.nih.gov).

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Tolerability

Side effects reported in the trial

Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.

Discontinued for side effects

11.3% (prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html) (11.3% vs 4.9% placebo (12 mg) · TRIUMPH-1 (12 mg, 80 wks, obesity))

Reported as 11.3% vs 4.9% placebo (12 mg). The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.

Had nausea

42.4% (prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html) (Nausea in the drug arm · TRIUMPH-1 (12 mg, 80 wks, obesity))

The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.

Nausea, diarrhea, constipation, and vomiting were the most common events, more frequent than placebo and generally mild-to-moderate, mainly during dose escalation.

From TRIUMPH-1 (12 mg, 80 wks, obesity) (Phase 3 sponsor topline figures; TRIUMPH-1 was published in NEJM on Sep 29, 2026). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source (prnewswire.com).

Studied together

Direct trial comparisons

Read the results for the exact products, doses, and participants studied.

Evidence

Clinical trials

27 of 33 registered studies indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (clinicaltrials.gov/study/NCT04881760)
    NCT04881760PHASE2Completed338 enrolled
    Has results
    Primary outcome: Mean Percent Change From Baseline in Body Weight

    Selected primary outcome

    Results · Nov 14, 2026 UTC

    Mean Percent Change From Baseline in Body Weight

    Least-squares mean · percent change · Baseline, Week 24

    Analysis population: All randomized participants who had baseline and at least one post-baseline body weight value, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.

    Placebo
    -1.55 percent change (clinicaltrials.gov/study/NCT04881760)

    Standard Error: 0.54 (clinicaltrials.gov)

    Overall outcome: 68 Participants (clinicaltrials.gov/study/NCT04881760) analyzed

    1 mg LY3437943
    -7.18 percent change (clinicaltrials.gov/study/NCT04881760)

    Standard Error: 0.67 (clinicaltrials.gov)

    Overall outcome: 69 Participants (clinicaltrials.gov/study/NCT04881760) analyzed

    4 mg LY3437943 (2 mg)
    -12.00 percent change (clinicaltrials.gov/study/NCT04881760)

    Standard Error: 0.71 (clinicaltrials.gov)

    Overall outcome: 33 Participants (clinicaltrials.gov/study/NCT04881760) analyzed

    4 mg LY3437943
    -13.80 percent change (clinicaltrials.gov/study/NCT04881760)

    Standard Error: 0.97 (clinicaltrials.gov)

    Overall outcome: 33 Participants (clinicaltrials.gov/study/NCT04881760) analyzed

    8 mg LY3437943 (2 mg)
    -16.64 percent change (clinicaltrials.gov/study/NCT04881760)

    Standard Error: 0.74 (clinicaltrials.gov)

    Overall outcome: 35 Participants (clinicaltrials.gov/study/NCT04881760) analyzed

    8 mg LY3437943 (4 mg)
    -18.26 percent change (clinicaltrials.gov/study/NCT04881760)

    Standard Error: 0.95 (clinicaltrials.gov)

    Overall outcome: 35 Participants (clinicaltrials.gov/study/NCT04881760) analyzed

    12 mg LY3437943 (2 mg)
    -17.39 percent change (clinicaltrials.gov/study/NCT04881760)

    Standard Error: 0.69 (clinicaltrials.gov)

    Overall outcome: 62 Participants (clinicaltrials.gov/study/NCT04881760) analyzed

    Outcome definition & treatment groups

    Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.

    Placebo: Participants received placebo matched to LY3437943 administered as SC injection QW.

    1 mg LY3437943: Participants received 1 mg LY3437943 administered as SC injection QW.

    4 mg LY3437943 (2 mg): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.

    4 mg LY3437943: Participants received 4 mg LY3437943 administered as SC injection QW.

    8 mg LY3437943 (2 mg): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.

    8 mg LY3437943 (4 mg): Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.

    12 mg LY3437943 (2 mg): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24

    Selected primary outcome

    Results · Nov 14, 2026 UTC

    Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24

    Least-squares mean · mL/min/1.73 m² · Baseline, Week 24

    Analysis population: All randomized participants who received at least one dose of study drug and had evaluable data for this specific outcome were included in the analysis. Data collected during the treatment period, defined as randomization through the earliest date of study intervention discontinuation or initiation of new sodium-glucose cotransporter-2 (SGLT2) inhibitor, angiotensin-converting enzyme (ACE) inhibitor, or angiotensin receptor blocker (ARB) were included.

    Placebo
    -0.19 mL/min/1.73 m² (clinicaltrials.gov/study/NCT05936151)

    Standard Error: 2.690 (clinicaltrials.gov)

    Overall outcome: 58 Participants (clinicaltrials.gov/study/NCT05936151) analyzed

    Retatrutide
    -1.62 mL/min/1.73 m² (clinicaltrials.gov/study/NCT05936151)

    Standard Error: 2.820 (clinicaltrials.gov)

    Overall outcome: 55 Participants (clinicaltrials.gov/study/NCT05936151) analyzed

    Outcome definition & treatment groups

    Measured glomerular filtration rate (mGFR) was determined from iohexol plasma clearance following a single iohexol injection and serial blood sampling. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 Body Surface Area (BSA)-indexed mGFR minus the baseline BSA-indexed mGFR and was reported in milliliters per minute per 1.73 square meters (mL/min/1.73 m²). Only participants with a non-missing baseline value and at least one post-baseline value were analyzed.

    Placebo: Participants received placebo matched retatrutide administered subcutaneously once weekly for approximately 24 weeks. To maintain blinding, participants followed a sham dose-escalation schedule with changes in administered volume every 4 weeks to match the retatrutide dose-escalation schedule.

    Retatrutide: Participants received retatrutide administered subcutaneously once weekly for approximately 24 weeks. Treatment was initiated at 2 mg once weekly and escalated every 4 weeks to 4 mg, 6 mg, 9 mg, and 12 mg. The target maintenance dose was 12 mg once weekly. Participants who did not tolerate the 12 mg dose could remain on a maintenance dose of 4 mg, 6 mg, or 9 mg.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity… (clinicaltrials.gov/study/NCT06383390)
    NCT06383390PHASE3Active_not_recruiting10,000 enrolled
  • A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (clinicaltrials.gov/study/NCT05929066)
    NCT05929066PHASE3Completed2,335 enrolled
  • A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (clinicaltrials.gov/study/NCT05882045)
    NCT05882045PHASE3Completed1,946 enrolled
  • A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (clinicaltrials.gov/study/NCT05929079)
    NCT05929079PHASE3Completed1,152 enrolled
  • A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (clinicaltrials.gov/study/NCT06859268)
    NCT06859268PHASE3Active_not_recruiting643 enrolled
  • A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (clinicaltrials.gov/study/NCT07357415)
    NCT07357415PHASE3Active_not_recruiting600 enrolled
  • A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (clinicaltrials.gov/study/NCT07035093)
    NCT07035093PHASE3Active_not_recruiting586 enrolled
  • Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet… (clinicaltrials.gov/study/NCT06354660)
    NCT06354660PHASE3Completed537 enrolled
  • A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (clinicaltrials.gov/study/NCT05931367)
    NCT05931367PHASE3Completed445 enrolled
  • Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With… (clinicaltrials.gov/study/NCT06297603)
    NCT06297603PHASE3Active_not_recruiting320 enrolled

Source: ClinicalTrials.gov API v2 (clinicaltrials.gov/search) · as of Nov 17, 2026

All trials on ClinicalTrials.gov (clinicaltrials.gov)
FDA enforcement archive

Recall records

Enforcement records describe specific recalled products and lots. They do not establish the recall status of every product containing the ingredient. openFDA does not maintain current recall status after classification; read the FDA record and any manufacturer notice for details.

1 indexed product record, ordered by FDA report date. One recall event may include several products.

D-0093-2026

Class IIFDA report: Oct 15, 2025

Recalling firm: GenoGenix LLC

Retatrutide for Injection, 60mg / 10mL vial, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

Browse the FDA enforcement archive (accessdata.fda.gov) · Source coverage & limitations (open.fda.gov)

Related

Related GLP-1s to compare

Updated automatically

What changed for Retatrutide

  • TrialResults posted for a Retatrutide study: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (clinicaltrials.gov/study/NCT05936151)
  • StudyRandomized trial in J Clin Endocrinol Metab: Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes (pubmed.ncbi.nlm.nih.gov/42135195)
  • StudyRandomized trial in Lancet: Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial (pubmed.ncbi.nlm.nih.gov/42810372)
  • StudyRandomized trial in N Engl J Med: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (pubmed.ncbi.nlm.nih.gov/42814954)
  • RecallRecall: Retatrutide for Injection, 60mg / 10mL vial, all presentations, GenoGenix, LLC, 2840 NW… (api.fda.gov/drug/enforcement.json)

Written from each source's own record as it changes. Every change on GLPcompare

Not legally for sale

FDA's warning letters naming Retatrutide

21 letters to companies selling it. Nobody can legally sell Retatrutide today.

  • TXP Innovations LLC dba Tex Peptides (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026)Aug 24, 2026
  • Royal Peptides LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026)Aug 24, 2026
  • NuScience Peptides LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026)Aug 24, 2026
  • Peptide Partners LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026)Aug 24, 2026
  • Peak Performance Peptides (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026)Aug 24, 2026
  • Gram Peptides (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026)Mar 31, 2026
  • Prime Sciences (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026)Mar 31, 2026
  • Mile High Compounds LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mile-high-compounds-llc-721600-03312026)Mar 31, 2026

Every FDA warning letter on GLP-1 sellers

ClinicalTrials.gov

What Retatrutide is studied for

Registered trials of this medicine by condition. A trial shows a question being asked, not that the answer is yes.

From PubMed

Latest Retatrutide trials and reviews

  • Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes (pubmed.ncbi.nlm.nih.gov/42135195)

    Randomized trial · J Clin Endocrinol Metab · Oct 1, 2026 · Pearson MJ et al. · cited by 1

  • Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (pubmed.ncbi.nlm.nih.gov/42814954)

    Randomized trial · N Engl J Med · Sep 29, 2026 · Jastreboff AM et al. · cited by 2

  • Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial (pubmed.ncbi.nlm.nih.gov/42810372)

    Randomized trial · Lancet · Sep 29, 2026 · Bellido V et al. · cited by 1

  • Systematic review and network meta-analysis of the safety and efficacy of the triple incretin receptor agonist, retatrutide compared to the dual incretin receptor agonist, tirzepatide, for treatment of type 2 diabetes mellitus (pubmed.ncbi.nlm.nih.gov/43005518)

    Meta-analysis · Ther Adv Endocrinol Metab · Sep 22, 2026 · Tereshchenko A et al.

  • Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes (pubmed.ncbi.nlm.nih.gov/42608321)

    Randomized trial · Diabetes Obes Metab · Aug 17, 2026 · Ruotolo G et al. · cited by 1

  • Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials (pubmed.ncbi.nlm.nih.gov/42371360)

    Meta-analysis · High Blood Press Cardiovasc Prev · Jun 29, 2026 · Simental-Mendía LE et al.

  • Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (pubmed.ncbi.nlm.nih.gov/42250575)

    Randomized trial · Lancet · Jun 6, 2026 · Bajaj HS et al. · cited by 21

  • Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis (pubmed.ncbi.nlm.nih.gov/41537067)

    Meta-analysis · Maedica (Bucur) · Dec 1, 2025 · Pallavi K et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

Common questions about Retatrutide

How much weight can you lose on Retatrutide?
In its pivotal trial (TRIUMPH-1 (Phase 3)), Retatrutide at 12 mg weekly (TRIUMPH-1) showed a mean body-weight change of -28.3% at 80 wks. This is a trial average; individual results vary. Source (prnewswire.com)
Is Retatrutide available yet?
No. Retatrutide is investigational (Phase 3) and not FDA-approved, so it cannot be prescribed or bought yet.
When will Retatrutide be FDA approved?
FDA has not approved Retatrutide, and no public record gives an approval date. It is at this stage: Phase 3. The trial registry lists 11 Phase 3 trials: 5 finished and 6 still running. The sponsor lists the last of those as finishing by February 2029, though a company can file with FDA before every trial ends. Source
Can you buy Retatrutide?
Not legally: FDA has not approved it, so no pharmacy can fill it. FDA says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." FDA has warned companies selling unapproved GLP-1 drugs labeled for research, and says: "The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health." FDA's warning letters naming it: 21 from Dec 10, 2024 to Aug 24, 2026. Source (fda.gov)
How much does Retatrutide cost?
It has no legal price, because it is not approved and nobody can legally sell it. Prices online are for unapproved products of unknown quality. What approved GLP-1s cost is on our price pages. Source
Does insurance cover Retatrutide?
No. It is not FDA approved, so it is on no plan's list, and an HSA or FSA has nothing legal to pay for. Coverage could only come after an approval. Source
Is there a generic Retatrutide?
No. It has no approved brand to copy. Anything sold as a generic of it is an unapproved product. Source
What is the Retatrutide dose?
There is no approved dose, because it has no FDA label. The result we cite was at 12 mg weekly (TRIUMPH-1). We do not publish dosing, units or mixing charts for an unapproved medicine: those charts online describe products FDA warns against.
How does Retatrutide work?
An investigational triple agonist targeting the GIP, GLP-1, and glucagon receptors; the glucagon arm is intended to increase energy expenditure.
Is Retatrutide a GLP-1?
Triple GIP, GLP-1, and glucagon receptor agonist. It is sometimes called a GLP-3, a nickname rather than a hormone or a drug class. Source
Who makes Retatrutide?
Eli Lilly.
Can you join a Retatrutide trial?
A clinical trial is one legal way to receive a medicine FDA has not approved. ClinicalTrials.gov shows 1 trial recruiting now, with who can enroll and where. Source (clinicaltrials.gov)
What are the side effects of Retatrutide?
Nausea, diarrhea, constipation, and vomiting were the most common events, more frequent than placebo and generally mild-to-moderate, mainly during dose escalation. Stopped because of side effects: 11.3% vs 4.9% placebo (12 mg). From TRIUMPH-1 (12 mg, 80 wks, obesity). These come from trials, not a label. Source (prnewswire.com)
How long does Retatrutide take to work?
Its Phase 2 trial reports weight at 24 and 48 weeks, so this says how far it had gone by then, not when it starts: mean change on 12 mg was -17.5% at 24 weeks and -24.2% at 48 weeks, against -1.6% and -2.1% on placebo. Source (pubmed.ncbi.nlm.nih.gov)